TNFRSF1B and depressive symptom measurement: Cross-sectional studies have found that post-treatment breast cancer survivors who report high levels of fatigue and depression also demonstrate higher levels of interleukin 1 receptor antagonist (sIL-1ra), interleukin 6 (IL-6), soluble IL-6 receptor (sIL-6r), soluble tumor necrosis factor receptor type II (sTNFR-II), and C-reactive protein (CRP) compared to those with low levels of symptomatology [31,32,33], although other studies of multiple cancer types have found no association [34,35,36].